Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib

Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib

Item
http://www.wikidata.org/entity/Q27025812
The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent CellsLoss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemiaThe HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo.Idelalisib in the management of lymphoma.Development of venetoclax for therapy of lymphoid malignancies.Ibrutinib: from bench side to clinical implications.Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia.Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-κB signalling instead of B-cell receptor signalling.Syk inhibitors in clinical development for hematological malignancies.New Insights into PI3K Inhibitor Design using X-ray Structures of PI3Kα Complexed with a Potent Lead Compound.Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.Kinase inhibitors in clinical practice: An expanding world.
P2860

Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib

Item
http://www.wikidata.org/entity/Q27025812
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Targeting neoplastic B cells a ...... e" of ibrutinib and idelalisib
@ast
Targeting neoplastic B cells a ...... e" of ibrutinib and idelalisib
@en
Targeting neoplastic B cells a ...... e" of ibrutinib and idelalisib
@nl
type
label
Targeting neoplastic B cells a ...... e" of ibrutinib and idelalisib
@ast
Targeting neoplastic B cells a ...... e" of ibrutinib and idelalisib
@en
Targeting neoplastic B cells a ...... e" of ibrutinib and idelalisib
@nl
prefLabel
Targeting neoplastic B cells a ...... e" of ibrutinib and idelalisib
@ast
Targeting neoplastic B cells a ...... e" of ibrutinib and idelalisib
@en
Targeting neoplastic B cells a ...... e" of ibrutinib and idelalisib
@nl
P1433
P1476
P2093
P275
P2860
P2888
P304
P31
P356
P407
P478
P50
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Targeting neoplastic B cells a ...... e" of ibrutinib and idelalisib
@en
P2093
P275
P2860
P2888
P304
P31
P356
P407
P478
P50
P577
P5875
P6179
P698
P921
P932